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Huntington’s disease (HD) is a progressive, late-onset neu-
rodegenerative illness with autosomal dominant inheri-
tance that affects one in 10 000 individuals in Western
Europe. The disease is caused by a polyglutamine repeat
expansion located in the N-terminal region of the hunt-
ingtin protein. The mutation is likely to act by a gain of
function, but the molecular mechanisms by which it leads
to neuronal dysfunction and cell death are not yet known.
The normal function of huntingtin in cell metabolism is
also unclear. There is no therapy for HD. Research on HD
should help elucidate the pathogenetic mechanism of this
illness in order to develop successful treatments to prevent
or slow down symptoms. This article presents new results
in HD research focusing on in vivo and in vitro model sys-
tems, potential molecular mechanisms of HD, and the
development of therapeutic strategies.
growing number of neurodegenerative disor-
ders have been found to belong to the group of CAG
triplet repeat disorders, including Huntington’s disease
(HD), spinal and bulbar muscular atrophy (SBMA),
dentatorubral palidoluysian atrophy, Machado-Joseph
disease/spinocerebellar ataxia type 3,and spinocerebel-
lar ataxias types 1, 2, 6, and 7.
1 All these illnesses are
caused by an elongated CAG repeat located in the cod-
ing region of the respective genes, which is translated
into a polyglutamine tract. The mechanism by which
CAG repeats elongate is currently unknown and is the
subject of intensive investigation.
2
Characteristic features of CAG repeat disorders are
autosomal dominant inheritance (except SBMA), late
onset,selective neurodegeneration,genetic anticipation,
a pathological threshold at which the mutation becomes
virulent, and an inverse correlation between CAG
repeat length and age at disease onset. The number of
glutamines in the normal (<35 residues) and abnormal
ranges (>35 residues) are similar in each disease pro-
tein,with the exception of spinocerebellar ataxia type 6
(SCA6). The disease proteins show no homology with
each other except the glutamine repeat,suggesting that
the elongated glutamine tract confers a toxic gain of
function to each disease protein. The current body of
evidence supports the hypothesis that expanded poly-
glutamine repeats undergo a conformational change
leading to abnormal protein–protein interactions, mul-
timerization, and the formation of insoluble protein
aggregates.
3-5 Indeed,abnormal neuronal inclusions have
been detected in the brains of patients.
6,7 Although the
causal relationship between aggregate formation and
disease remains to be proven,the gradual deposition of
disease protein in neurons is consistent with the late
onset and progressive nature of symptoms.Furthermore,
the process of aggregate formation is ultimately associ-
ated with degeneration of mammalian cells.
8 Analysis
of in vitro and in vivo model systems support the
hypothesis that glutamine repeat disorders, like
Alzheimer’s disease and Parkinson’s disease,are caused
by an aggregation-based pathogenetic mechanism.How-
ever,there are also studies that suggest that the process
of aggregate formation may even be beneficial to neu-
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9,10Aggregation as the main detrimental factor
in neurodegeneration in HD and related illnesses has
been a debated issue in recent years.
This article will describe recent advances in under-
standing the pathogenesis of HD,the most common and
most studied of the glutamine repeat disorders.Different
model systems for the screening and analysis of potential
therapeutic molecules have been established and have
yielded exciting results with regard to halting the for-
mation of insoluble protein aggregates.
Clinical features 
and neuropathology of 
Huntington’s disease
HD begins gradually with mood disturbances,increasing
involuntary movements (chorea),and cognitive impair-
ment, finally leading to dystonia and severe dementia.
The first symptoms typically appear in mid-life (late
fourth and fifth decade);however,there are also juvenile
and late-onset cases.Within 15 to 20 years after its onset,
the disease inexorably progresses to death.Mood abnor-
malities often start appearing a few years before move-
ment dysfunction, which comprises both involuntary as
well as impaired voluntary movements. Chorea is
observed in ~90% of all HD patients and increases dur-
ing the first 10 years of the illness,while dystonia is infre-
quent in the early symptomatic period but becomes
prominent at the late stages of the illness.Cognitive dis-
turbances begin with a loss of mental flexibility and
progress to profound dementia.
The clinical progression of HD is associated with degen-
eration of the striatum.HD is classified into five patho-
logical grades, ranging from microscopically unde-
tectable abnormalities of patient brains to extensive
atrophy.
11All grades exhibit a loss of brain weight (up to
30%) resulting from neuronal cell death.The extent of
neuronal cell death is directly related to the severity of
disease.In the basal ganglia,the caudate nucleus is more
severely affected than the putamen or the globus pal-
lidus. The specific progressive atrophy in these brain
regions is associated with reactive astrocytosis.
12 Within
the striatum there is selective loss of medium spiny
GABA (γ -aminobutyric acid)–ergic neurons,which pro-
ject into the pallidum forming the indirect striatopallidal
pathway. Prior to cell death, neuronal dysfunction is
manifested by abnormalities of dendritic endings. In
addition to atrophy in the striatum, extensive neuronal
cell loss also occurs in the deep layers of the cerebral
cortex, white matter, hippocampus, amygdala, and thal-
amus.
13 
The disease gene 
and its protein
The human HD gene is located in the chromosomal
region 4p16.3 and was isolated by positional cloning
approaches.
14 It contains 67 exons and encodes the hunt-
ingtin protein of 3144 residues with a molecular mass
of about 350 kd. The mutation underlying HD is an
unstable CAG trinucleotide repeat expansion in the first
exon of the gene.It ranges from 6 to 37 units in healthy
individuals, and 38 to 180 units in HD patients.
15,16 The
CAG repeat is translated into a polyglutamine stretch,
which is conserved in vertebrates, containing 7 gluta-
mines in the mouse
17 and only 4 in the puffer fish,
18 but is
absent from the Drosophila protein.
19 The predicted
huntingtin protein sequence is highly conserved between
human,mouse,and puffer fish,but shows no significant
homology with other proteins in databases. The only
functional motives that have been discovered are a puta-
tive leucine zipper and a HEAT repeat.
20 HEAT repeats
consist of two hydrophobic α -helices and were found in
proteins involved in cellular transport processes. We
have found that the huntingtin interacting protein–1
(HIP1) associates with the HEAT repeat.
21 However,
whether this sequence motive is essential for
protein–protein interaction remains to be determined.
HIP1 has been identified using the yeast two-hybrid sys-
tem. The predicted amino acid sequence of HIP1
exhibits significant similarity to cytoskeleton proteins,
suggesting that HIP1 and the huntingtin protein play a
functional role in the cell filament networks and/or vesi-
cle trafficking.For example,HIP1 is homologous to the
yeast protein Sla2p,
22 which associates with the mem-
brane cytoskeleton and plays a functional role in endo-
cytosis.
23 Recently,colocalization of HIP1 and huntingtin
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HAP1 huntingtin-associated protein–1
HD Huntington’s disease
HIP1 huntingtin interacting protein–1
NII neuronal intranuclear inclusion
SBMA spinal and bulbar muscular atrophy19
with clathrin-coated vesicles in mammalian cells has
been described,suggesting that both proteins also play a
functional role in endocytosis in higher eukaryotes.
24,25
This hypothesis is substantiated by the finding that hunt-
ingtin and its associated protein, huntingtin-associated
protein–1 (HAP1),
26 are transported along microtubules
in axons.
27 Furthermore, direct binding of HAP1 with
p150Glued of the dynactin complex,which is critical for
retrograde movement of vesicles along microtubules,
has been described.
28 Together these findings indicate
that a protein complex consisting of the proteins HIP1,
HAP1, and huntingtin is functionally involved in endo-
cytosis and retrograde transport of clathrin-coated vesi-
cles along microtubules.However,additional cell biology
and biochemical studies will be necessary to address this
hypothesis in more detail.
Using the yeast two-hybrid system we have also demon-
strated that the SH3-containing Grb2-like protein
SH3GL3 associates with huntingtin.
29 This protein is
preferentially expressed in brain and testis and selec-
tively interacts with the proline-rich region in huntingtin,
which is located immediately downstream of the polyg-
lutamine tract. The SH3GL3 protein, as well as its
homologous proteins SH3GL1 and SH3GL2, belongs
to a novel SH3-containing protein family. Members of
this family contain the SH3 domain at the C-terminus
that is evolutionarily conserved and drives protein–pro-
tein interactions through proline-rich ligands.
30 In the
central nervous system,these proteins play a major role
in the signal transduction from membrane receptors and
the regulation of the exocytic/endocytic cycle of synaptic
vesicles.
31 Thus, enhanced binding of SH3GL3 to hunt-
ingtin with a polyglutamine sequence in the pathological
range (eg,50 glutamines) could result in dysregulation of
the endocytic/exocytic cycle in mammalian cells.
In order to address the functional role of huntingtin,HIP1,
and SH3GL3 in synaptic vesicle transport in more detail,
the homologous mouse genes were mapped and cloned.
32-34
The generation of HIP1 and SH3GL3 knockout as well as
transgenic animal models will help elucidate the normal
function of huntingtin and may also help to understand the
key steps in the pathogenesis of HD.
Neuronal inclusions 
and neuropathology
In order to study the effect of an elongated polygluta-
mine sequence on neuronal dysfunction and neurode-
generation in vivo,Mangiarini et al
35 generated the first
HD transgenic mice. In these animals, exon 1 of the
human HD gene carrying a CAG repeat of 115 to 156
units was expressed under the control of the HD pro-
moter. Strikingly, expression of the mutant huntingtin
fragment resulted in the development of a progressive
neurological phenotype very similar to HD, including
tremor, epileptic seizures, involuntary movements, and
cell loss. This indicates that expression of a truncated
huntingtin fragment with a polyglutamine sequence in
the pathological range is sufficient for the development
of a neurological phenotype with characteristic features
of HD.
Davies et al
36 observed that these transgenic animals
developed pronounced neuronal intranuclear inclusions
(NIIs) containing huntingtin and ubiquitin prior to the
development of the neurological phenotype,indicating
that formation of NIIs is a prerequisite for the devel-
opment of neuronal dysfunction in HD.
Within the last few years, several other laboratories
have confirmed the appearance of NIIs using different
transgenic mouse models of HD.
37-39 Full-length hunt-
ingtin protein as well as truncated versions of the pro-
tein with a polyglutamine sequence in the pathologi-
cal range (40-150 glutamines) were expressed in mice
under the control of different promoters.The majority
of these studies suggest that the formation of NIIs is
correlated with the appearance of progressive neu-
ronal dysfunction and toxicity.Thus, it is reasonable
to assume that reduction of inclusion body forma-
tion and huntingtin aggregation may have a benefi-
cial effect on disease progression in HD patients.
Using a conditional mouse model of HD,Yamamoto
et al
40 demonstrated that blocking the expression of
mutant huntingtin protein in neurons resulted in the
disappearance of inclusions and the behavioral phe-
notype. Therefore, reduction of HD protein expres-
sion in patients and/or stimulation of natural clear-
ance mechanisms could be effective therapeutic
strategies for HD.
Apart from NIIs,inclusion bodies with aggregated hunt-
ingtin protein were recently detected in axons and axon
terminals of striatal neurons.
41 These structures were
termed neuropil aggregates. The formation of these
aggregates is likely to affect specific neuronal functions
such as axonal transport and neurotransmitter release or
uptake in axon terminals. Therefore, the deposition of
mutant huntingtin protein in the terminals of striatal
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neurons,which are affected most in HD,may contribute
to the selective neuropathology of HD.
After the discovery of NIIs in brains of transgenic ani-
mals,
35 similar structures were detected in postmortem
brains of HD patients.
6,7 NIIs were found in neurons
but not in glia cells. Immunohistochemical studies
showed that they are most abundant in the striatum
and the cerebral cortex, the areas most affected by
HD. In the striatum, inclusions were found in the
medium spiny neurons that are selectively lost during
HD. NIIs in patient brains are detected by antibodies
directed against the N-terminus of huntingtin,but not
by antibodies that recognize the C-terminus of the
protein, indicating that a truncated N-terminal hunt-
ingtin fragment rather than the full-length protein is
present in the NIIs of patients. Like the NIIs in trans-
genic animals, the NIIs in patients were stained with
anti-ubiquitin antibodies. These results suggest that
the truncated huntingtin protein present in the inclu-
sion bodies is ubiquitinated but cannot be degraded by
the proteasome system.
42 Ultrastructural studies
revealed that NIIs in patient brains contain aggregated
huntingtin protein with a fibrillar and granular mor-
phology. In addition, dystrophic neurites containing
aggregated huntingtin protein were detected.
6 Dys-
trophic neurites are known to result from dysfunction
of neuronal retrograde transport. Formation of insol-
uble huntingtin aggregates could alter this process in
neuronal cells.
It remains unclear to date whether the formation of
NIIs,dystrophic neurites,or neuropil aggregates is the
cause or merely a consequence of neurodegenerative
disorders. Using neuronal cell culture model systems
and transgenic animals, Saudou et al
9 and Klement et
al
10 presented evidence that the formation of inclusion
bodies could be nontoxic or even beneficial to neu-
ronal cells. They showed that overexpression of dis-
ease proteins with a polyglutamine sequence in the
pathological range is toxic for neuronal cells,but inclu-
sion formation does not contribute to toxicity. How-
ever, using cell culture as well as transgenic animal
model systems in the presence of more physiological
amounts of mutant huntingtin,cell death was observed
only after fibrillar structures had formed. We there-
fore propose that formation of aggregates and subse-
quently of inclusion bodies is a key step in the devel-
opment of late-onset progressive neurodegenerative
disorders.
Huntingtin protein aggregation 
and therapeutic strategies
If aggregation is crucial, preventing aggregation must
slow down disease progression. We have developed a
number of in vitro and in vivo strategies to address this
issue, the creation of a drug screen assay being one of
them.
Formation of insoluble huntingtin protein aggregates
was reproduced in vitro. We found that HD exon 1
protein fragments with polyglutamine tracts in the
pathological range (>37 glutamines), but not with a
polyglutamine tract in the normal range (20-32 gluta-
mines), form high-molecular-weight protein aggre-
gates.
5,43 Electron micrographs of these aggregates
revealed a characteristic fibrillar or ribbon-like mor-
phology, reminiscent of scrapie prion rods and the β -
amyloid fibrils found in Alzheimer’s disease.
5 The fib-
rillar structures are thought to result from the
polyglutamine sequences acting as “polar zippers.”
Perutz
3 proposed that expansion of polyglutamine
repeats beyond a critical length of 41 glutamines may
lead to a phase change from random coils to hydro-
gen-bonded hairpins that self-assemble into insoluble
protein aggregates.Our in vitro experiments with glu-
tathione S-transferase (GST)–HD exon 1 fusion pro-
teins support this hypothesis,suggesting that the struc-
tural transition caused by expansion and required for
aggregate formation occurs between 32 to 37 gluta-
mines. Polyglutamine tracts with 37 or more gluta-
mines readily self-assemble into insoluble protein
aggregates, whereas polyglutamine tracts with less
than 32 glutamines did not show any evidence of fibril
formation. Interestingly, it has been shown that the
pathological range of the polyglutamine sequence in
HD is between 38 to 41 glutamines, with no HD case
reported with fewer than 38 glutamines, nor any indi-
vidual with more than 41 glutamines having remained
unafflicted by HD.The threshold for the formation of
insoluble huntingtin fibrils in vitro is remarkably sim-
ilar to the pathological threshold in HD.
Jarrett and Lansbury
44 proposed that the self-assembly
of β -amyloids into fibrillar structures in Alzheimer’s dis-
ease occurs by a nucleation-dependent mechanism.We
found that the formation of amyloid-like huntingtin fib-
rils in vitro and in vivo critically depends on polygluta-
mine repeat length,protein concentration,and time.Fur-
thermore, huntingtin aggregation can be seeded by21
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preformed fibrils, suggesting that fibrillogenesis in HD,
as in Alzheimer’s disease,is caused by nucleation-depen-
dent polymerization.
43 Our findings that the assembly
of huntingtin aggregates requires the formation of a
nucleus and is time- and protein concentration–depen-
dent may account for the late onset and progressive phe-
notype in HD.Although fibril formation occurs within
hours in the in vitro system, it may take years in neu-
ronal cells of HD patients.The concentration of mutant
huntingtin in medium spiny neurons,which are affected
most in HD,is unknown,but it is likely to be much lower
than that used in the in vitro aggregation assays.Thus,we
suggest that the lag time during which huntingtin dimers,
trimers,and oligomers are formed in vivo is significantly
elongated in HD patients.
For the identification of huntingtin aggregation inhi-
bitors, we have developed a rapid and sensitive filter
retardation assay, which is suitable for the high-
throughput screening of drugs that prevent aggregate
formation.
45 This assay is based on the finding that
HD exon 1 aggregates are insoluble in sodium dode-
cyl sulfate (SDS) and are retained on a cellulose
acetate filter, whereas monomeric forms of the HD
exon 1 protein do not bind to this filter membrane.
The captured aggregates are then detected by simple
immunoblot analysis using a specific anti-huntingtin
antibody. Using the filter retardation assay, we first
tested a number of known inhibitors of β -amyloid,
PrP
scr, and microtubule fibril formation for their effect
on huntingtin aggregation in vitro.
46 We found that
Congo red, thioflavine S, chrysamine G, and Direct
fast yellow inhibited HD exon 1 protein aggregation
in a dose-dependent manner, whereas other potential
inhibitors of β -amyloid formation, such as thioflavine
T, gossypol, melatonin, and rifampicin, had little or
no effect on huntingtin aggregation. The results
obtained in vitro were confirmed in cell culture model
systems. Furthermore, we found that the monoclonal
antibody 1C2, which specifically recognizes the elon-
gated polyglutamine stretch in huntingtin, and the
heat shock proteins Hsp70 and Hsp40 are potent
inhibitors of huntingtin aggregation.
46,47 Interestingly,
the addition of heat shock proteins to in vitro aggre-
gation reactions shifts the self-association pathway of
huntingtin from fibrillar to amorphous aggregation.
This suggests that in vivo chaperones may have the
potential to transform toxic fibrillar aggregates into
nontoxic aggregates, which can then be degraded by
the ubiquitin/proteasome system. Thus, small mole-
cules that activate a heat shock response in neurons
may be effective in delaying the onset and progression
of HD. However, additional research using in vitro
and in vivo model systems will be required to show
whether an increase in chaperone levels in neurons
is a viable therapeutic strategy.
Conclusions
Inhibition of huntingtin fibrillogenesis by small mole-
cules is a very attractive therapeutic strategy.Drugs that
bind to the mutant huntingtin protein should delay the
onset and progression of HD.The future challenge will
be to find small chemical compounds that have reason-
able brain permeability,and per se are nontoxic to neu-
ronal cells. In order to find such compounds, we have
performed high-throughput screening using an auto-
mated filter retardation assay. Within the last year we
have tested more then 180 000 different chemical com-
pounds and identified about 700 small molecules that
prevent huntingtin aggregation in vitro. These com-
pounds are currently being tested in cell culture model
systems of HD. We were able to reduce aggregate for-
mation in mammalian cells; as a consequence, cytotoxi-
city was lowered. This is a very important finding,
because it shows for the first time that there is a direct
link between the process of aggregate formation and
disease. The next challenge will be to test these sub-
stances in transgenic animals for their ability to cross
the blood–brain barrier,to dissolve neuronal inclusions
or prevent their formation, and to reduce neurodegen-
erative symptoms. If this proves successful, one could
think of moving on to clinical trials.Since the identifica-
tion of the gene for Huntington’s chorea in 1993, this
would represent a major milestone in HD research and
also in molecular medicine generally, because for the
first time a causal therapy for an inherited disease would
be within reach.It would also have positive implications
for functional genomics, because it would be the first
time the strategy of finding a gene with a positional
cloning approach and subsequent functional analysis
and characterization of the pathogenetic mechanism had
been able to lead to a causal therapy of an illness.❏
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Enfermedad de Huntington: desde los genes
a la potencial terapia
La Enfermedad de Huntington (EH) es una pato-
logía progresiva, neurodegenerativa, de aparición
tardía con herencia autosómica dominante que
afecta a uno en 10 000 individuos en Europa
Occidental. La enfermedad es causada por una
expansión repetida de poliglutamina ubicada en
la región N-terminal de la proteína huntingtina.
La mutación es probable que actúe por un
aumento de la función, pero los mecanismos
moleculares que conducen a la disfunción neuro-
nal y la muerte celular aún no se conocen. La fun-
ción normal de la huntingtina en el metabolismo
celular tampoco está aclarada. No hay tratamien-
to para la EH. La investigación en la EH debe ayu-
dar a esclarecer los mecanismos patogenéticos de
esta enfermedad en orden a desarrollar trata-
mientos exitosos para prevenir o reducir los sín-
tomas. Este artículo presenta nuevos resultados
en la investigación de la EH focalizados en siste-
mas modelo en vivo e in vitro, potenciales meca-
nismos moleculares de la EH y el desarrollo de
estrategias terapéuticas.
La maladie de Huntington : du gène au 
traitement potentiel
La maladie de Huntington (MH) est une patholo-
gie neurodégénérative progressive d’apparition
tardive à transmission dominante autosomique
qui atteint un individu sur 10 000 en Europe de
l’Ouest. Une amplification génique de la polyglu-
tamine située sur la région N-terminale de la pro-
téine huntingtin est à l’origine de la maladie. La
mutation agit probablement par l’intermédiaire
d’un gain fonctionnel mais les mécanismes molé-
culaires qui conduisent à la dysfonction neurona-
le et à la mort cellulaire ne sont pas encore
connus. Le rôle normal de la protéine huntingtin
dans le métabolisme cellulaire est également obs-
cur. Il n’existe pas à l'heure actuelle de traitement
pour la MH. La recherche devrait fournir des
éclaircissements sur les mécanismes pathogé-
niques de la maladie et permettre le développe-
ment de thérapeutiques capables de prévenir ou
de ralentir les symptômes. L’article qui suit pré-
sente les nouveaux résultats de la recherche dans
la MH, tout particulièrement ceux concernant les
systèmes de modélisation in vivo et in vitro, les
mécanismes moléculaires potentiels de la MH et
le développement des stratégies thérapeutiques.
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